Shares of HENLIUS (02696) plummeted 10.53% in the intraday trading session on Thursday, following the rejection of Chinese conglomerate Fosun International's buyout offer by Hong Kong shareholders.
The rejected offer, which valued the drugmaker at HK$13.37 billion ($1.72 billion), proposed a buyout price of HK$24.60 per share. Fosun unit Shanghai Fosun Pharmaceutical, which already holds a 59.6% stake in HENLIUS, failed to secure the requisite majority approval from H-class shareholders for the privatization proposal.
The sharp decline in HENLIUS's stock price reflects investors' disappointment with the failed buyout attempt. The rejection of the offer raises concerns about the company's future prospects and potential challenges in securing alternative funding or strategic partnerships.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。